Yaz Settlement Negotiations Ordered as First Trial in MDL Delayed

The federal judge presiding over thousands of Yaz lawsuits and Yasmin lawsuits has delayed the first trial scheduled to begin next week, ordering the parties to meet with a special mediator in an attempt to negotiate a settlement for the litigation. 

The first Yaz trial was expected to begin on January 9, involving a plaintiff who suffered a pulmonary embolism after taking the birth control pill.

In an order issued December 31, Judge Herndon indefinitely continued the start of that case and ordered the parties to engage in Yaz settlement negotiations.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Learn More

Judge Herndon determined that the best interests of the litigation will be better served by delaying the start of the bellwether trial, which was designed to help the parties gauge how juries are likely to respond to evidence that will be presented in many of the cases.

Instead, Professor Stephen Saltzburg of George Washington School of Law was appointed to serve as Special Master for purposes of mediating the entire litigation. The leadership teams for the plaintiffs and Bayer were ordered to meet with Professor Saltzburg and to negotiate in good faith.

Over 10,000 women have filed a lawsuit against Bayer alleging that they suffered injuries as a result of the drug maker’s failure to adequately warn about the side effects of Yaz, Yasmin and other drosperinone-based birth control pills made by Bayer.

Drospirenone is a newer type of progestin that is used in combination oral contraceptives that also include estrogen. It was originally introduced by Berlex Laboratories in Yasmin. Once Berlex was acquired by Bayer Healthcare an updated version of Yasmin was introduced called Yaz. More recently, Bayer introduced a third version, marketed as Beyaz, which includes a folate supplement. Generic versions of Yaz and Yasmin are also now available from other manufacturers. Generic versions of Yaz and Yasmin include Ocella, Gianvi, Loryna, Safyral, Syeda and Zarah.

Several studies have suggested that women using Yaz face an increased risk of suffering a blood clot, stroke, pulmonary embolism, deep vein thrombosis and sudden death.

The FDA recently released a report that suggested drospirenone-based birth control pills may increase the risk of blood clots by 75% over older birth control pills. They also doubled the risk of heart attacks and strokes in users who were new to birth control, with some health problems appearing in less than three months after women started to take the pills.

A panel of FDA advisors which met in early December called for stricter label warnings on Yaz and Yasmin, but stopped short of recommending a Yaz recall.

All federal Yaz and Yasmin lawsuits have been consolidated as part of an MDL, or multidistrict litigation, which is centralized before Judge Herndon in the U.S. District Court for the Southern District of Illinois.

Saltzburg was recently the mediator that helped reach settlements in thousands of lawsuits over the side effects of Seroquel; an antipsychotic by AstraZeneca which many say causes diabetes and weight gain. In July, AstraZeneca reported it had reached settlements in more than 28,000 of those claims.

1 Comments

  • KatherineJanuary 4, 2012 at 10:35 pm

    I would like to share with everyone about these lawsuits,please don't think you are going to get rich off of your lawsuit, it will be like the Heparin lawsuits that killed alot of people including my mother,there will be settlement offers very low offers and you will be told by your lawyers to take it,after all the fees are taken out you will be left with nothing for everything you have went thro[Show More]I would like to share with everyone about these lawsuits,please don't think you are going to get rich off of your lawsuit, it will be like the Heparin lawsuits that killed alot of people including my mother,there will be settlement offers very low offers and you will be told by your lawyers to take it,after all the fees are taken out you will be left with nothing for everything you have went throw,you will feel like they slaped you in the face and told you a pack of lies like they did us and many more people like us,so be ready to feel like they didn't care about what you have been throw,because they don't..please read the articles and comments on about lawsuits and you will see the resuils of what has happens to alot of people.Read there stories we all can't all be wrong.I am really sorry about what has happen to you ,just bewear.

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal
BioZorb Lawsuit Alleges Breast Tissue Marker Failed, Requiring Surgical Removal (Posted 2 days ago)

A BioZorb lawsuit has been filed by several breast cancer survivors after the BioZorb implants moved out of place and failed to dissolve int he body, requiring surgical removal.

Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October
Fairness Hearing For Philips CPAP Recall Medical Monitoring Settlement Set for October (Posted 2 days ago)

A U.S. District Court judge has scheduled a fairness hearing for October in order to determine whether final approval should be granted to a $25 million Philips CPAP recall settlement agreement, which would pay former users $25 million to pay for future medical monitoring needs.